Nanosonics Limited (ASX:NAN): FY2026 Results, trophon Demand and CORIS Launch Plans

Aditi Sarkar

21 October 2026 03:23 PM AEDT

Nanosonics Limited (ASX:NAN): FY2026 Results, trophon Demand and CORIS Launch Plans

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Nanosonics Limited (ASX:NAN) reported FY2026 revenue of AUD 203.9 million, up 3%.
Annual trophon placements reached 4,230 units; the cumulative installed base rose to 39,230.
EBIT was AUD 16.0 million and attributable net profit was AUD 17.8 million.
Management outlined FY2027 revenue guidance of AUD 220–228 million at constant currency.

Nanosonics Limited develops and supplies automated infection-prevention technology used to reprocess medical devices. Its current activities centre on ultrasound-probe disinfection and preparations to commercialise a separate endoscope-cleaning system. Following its August 2026 full-year results, Nanosonics Limited (ASX:NAN) closed at AUD 3.05 on 20 October 2026, up 1.67% for the session. The company’s recent disclosures also set out product placements, cash reserves and spending plans for the financial year ending June 2027.

Company Business

The Sydney-based company sells trophon equipment for high-level disinfection of ultrasound probes. The business also generates recurring income from disinfection consumables, accessories, service and replacement parts. Its product range includes trophon3 and the trophon2 Plus software upgrade, alongside technical support and probe-compatibility testing with equipment manufacturers.

Nanosonics (ASX:NAN) operates in North America, Europe, the United Kingdom and Asia-Pacific. North America accounts for a major share of device placements, while the company’s newer CORIS system is designed for automated cleaning of flexible endoscopes. Unlike an established trophon installation, CORIS is still in the transition from controlled release to broader commercial sales.

Recent Development

In its August 2026 results, Nanosonics reported 4,230 trophon placements for the year ended 30 June, a 9% increase. The cumulative installed base rose 6% to 39,230 devices, with 2,230 units added to that measure. North American placements reached 3,880, while upgrades in that region increased 32% to 1,980 units.

Nanosonics (ASX:NAN) also reported progress with controlled market releases of CORIS. Trial deployments extended to Australia, the United Kingdom, Ireland and the United States. The company described regulatory clearances across Australia, Europe and the United Kingdom, alongside an initial US Food and Drug Administration clearance and a further US submission for expanded indications.

In August, the board announced an on-market share buyback of up to AUD 40 million for FY2027. This followed AUD 20 million of shares repurchased during FY2026. The programme remains a capital-allocation decision rather than an indicator of future share-price performance.

Financial Performance and Sector Context

FY2026 statutory revenue reached AUD 203.9 million against AUD 198.6 million in FY2025, an increase of approximately 3%. Capital revenue was AUD 54.7 million and recurring revenue AUD 149.2 million. At constant currency, management reported revenue of AUD 211.5 million, up 6%, highlighting the effect of exchange rates on Australian-dollar reporting.

Operating expenses were AUD 141.4 million, compared with AUD 138.7 million in the previous financial year. Earnings before interest and tax declined to AUD 16.0 million from AUD 17.8 million. Attributable net profit was AUD 17.8 million, compared with AUD 20.7 million. Gross margin reduced to 76.9% from 78.2%, with product mix and currency translation among the stated factors.

For Nanosonics (ASX:NAN), the established trophon business generated AUD 50.6 million in segment-level EBIT under the company’s allocation methodology. This differs from consolidated EBIT because development and commercialisation expenditure for CORIS is excluded from that measure. The distinction matters when comparing recurring equipment economics with total group profitability.

Cash and cash equivalents stood at AUD 155.2 million at 30 June 2026, with no debt reported. Nanosonics described AUD 13.6 million of cash generation excluding the completed AUD 20 million buyback. Medical-device reprocessing remains dependent on healthcare purchasing cycles, clinical requirements, product validation and jurisdiction-specific regulatory permissions.

Risks to Consider

Product acceptance, competition, manufacturing costs and clinical procurement timing can affect sales and margins. Nanosonics (ASX:NAN) also faces exchange-rate exposure because much of its revenue is earned in US dollars. CORIS expansion depends on regulatory indications, customer training, field execution and additional commercial expenditure. The company has identified tariffs, freight costs and planned investment as relevant FY2027 cost considerations.

What to Watch Next

For FY2027, management provided constant-currency revenue guidance of AUD 220–228 million, a gross-margin range of 74–76% and operating expenses of AUD 156–163 million. The projections assume the trade environment and US tariffs remain at the levels described in the results announcement; they are company guidance, not realised results.

Nanosonics (ASX:NAN) planned CORIS commercial launches in the UK, Ireland and Australia during the first half of FY2027, followed by the US. The company indicated that initial CORIS revenue could be in the low single-digit millions of Australian dollars. Subsequent disclosures will establish the actual timing, sales contribution and expense profile. The annual general meeting was scheduled for 4 November 2026.

Key Insights

FY2026 showed additional trophon installations and recurring revenue alongside lower statutory EBIT and net profit. The debt-free cash position provides financial context for planned CORIS expenditure and the announced buyback. For Nanosonics (ASX:NAN), subsequent quarterly or half-year updates on equipment placements, new-product commercialisation, foreign-exchange effects and cash flows will be important factual measures of progress.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.